Clinical Trial Update: A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 prospective, randomized trial evaluating different doses of famitinib malate in combination with camrelizumab for recurrent and metastatic cer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer Metastatic
• Cervical Cancer Recurrent

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib malate (famitinib malate)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Cervical Cancer Metastatic, Cervical Cancer Recurrent | Phase 2 | Status: NOT_YET_RECRUITING